trial
as of 2026-07-01Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
NCTId NCT03870880
at a glance
Phase 3 · Completed
Enrollment 215 (actual)
Sponsored by Rovi Pharmaceuticals Laboratories
Primary completion 2020-01-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
215 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2017-08-25
Primary completion
2020-01-08
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Rovi Pharmaceuticals LaboratoriesLead Sponsor
Investigators
2
Robert Litman, MDPrincipal Investigator
Yuriy FiltsPrincipal Investigator
Sites
24 total
Rogers, United StatesGarden Grove, United StatesLong Beach, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesHialeah, United StatesHollywood, United StatesGaithersburg, United StatesLas Vegas, United StatesBerlin, United StatesDayton, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
215
Phase
PHASE3
Primary Completion Date
2020-01-08
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person
person